Research Progress on Cyclic-Peptide Functionalized Nanoparticles for Tumor-Penetrating Delivery
Chenkai Wang,Zefan Shen,Yiyang Chen,Yifan Wang,Xuanyi Zhou,Xinyi Chen,Yuhang Li,Pu Zhang,Qi Zhang
DOI: https://doi.org/10.2147/ijn.s487303
IF: 7.033
2024-11-28
International Journal of Nanomedicine
Abstract:Chenkai Wang, 1, 2 Zefan Shen, 1, 2 Yiyang Chen, 1, 2 Yifan Wang, 2 Xuanyi Zhou, 2 Xinyi Chen, 1 Yuhang Li, 2 Pu Zhang, 2 Qi Zhang 2 1 The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China; 2 Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, People's Republic of China Correspondence: Qi Zhang; Pu Zhang, Email ; A key challenge in cancer treatment is the effective delivery of drugs into deep regions of tumor tissues, which are impermeable due to abnormal vascular network, increased interstitial fluid pressure (IFP), abundant extra cellular matrix (ECM), and heterogeneity of tumor cells. Cyclic peptides have been used for the surface engineering of nanoparticles to enhance the tumor-penetrating efficacy of drugs. Compared with other surface ligands, cyclic peptides are more easily produced by automated chemical synthesis, and they are featured by their higher binding affinity with their targets, tumor selectivity, stability against degradation, and low toxicity. In this review, different types of cyclic peptides, their physicochemical properties and their in vivo pharmacokinetics are introduced. Next, the progress of cyclic peptide-functionalized drug delivery nanodevices is updated, and the mechanism underlying the tumor-penetrating properties of cyclic peptide-functionalized drug delivery nanodevices is discussed. Keywords: cyclic peptide, tumor penetration, drug delivery, nanomaterial functionalization Cancerous tissues are characterized by several distinctive features that impede the delivery of therapeutic agents: an abnormal vascular network, elevated interstitial fluid pressure (IFP), a dense extracellular matrix (ECM), and tumor cell heterogeneity. The ECM is composed of collagen, elastin fibers, proteoglycans, and glycosaminoglycans, which form a complex, cross-linked gel-like structure. This structure significantly hinders the diffusion of drugs within the tumor interstitium. Additionally, IFP increases from the tumor periphery to the center, creating a barrier that prevents nanocarriers and drug molecules from penetrating deep into the tumor after extravasation from peripheral blood microvessels. Moreover, the tumor's vascular network is highly heterogeneous, resulting in poor perfusion and necrosis. This heterogeneity increases the diffusion distance that nanomedicines must cover to reach target cells. Consequently, most clinically approved drugs, including small molecules, antibodies, hormones, peptides, oncolytic viruses, and nanoparticles, face challenges in penetrating solid tumors. 1–3 To overcome these barriers, there is an urgent need to develop vehicles capable of deep tumor penetration to effectively deliver drugs to targeted lesions. In recent years, many researchers have proposed the potential of cyclic peptides as surface engineering ligands to functionalize drugs or drug delivery systems. The unique structures of cyclic peptides are organized as amino acids connection in a cyclic manner, and they have many advantages in drug delivery into tumors. Cyclic peptides have been engineered to precisely target tumor cells by binding to receptors that are excessively present on the surface of these cells. 4,5 These cyclic structures offer greater stability compared to their linear counterparts, as they are less likely to be broken down by proteases due to their rigid, closed-ring shape which restricts conformational changes. Additional stability can be achieved through modifications such as N-methylation of the peptide backbone or by forming covalent bonds. 6 These alterations can enhance cyclic peptides' bioavailability, specificity, and ability to penetrate cell membranes, making them potentially more effective in certain therapeutic applications. Most importantly, the cyclic peptide showed enhanced tumor-penetrating ability. The underlying mechanism is the enhanced transmembrane transport and the enhanced transcellular transport of the cyclic peptide. Thanks to the excellent bioactivity of the cyclic peptide, cyclic-peptide-functionalized drugs or drug delivery systems can more effectively translocate across cancerous tissue barriers, and changing their physical and chemical properties, such as size, charge and hydrophobicity, can regulate their tumor-penetrating efficiency. However, as far as we can know, a comprehensive understanding of the tumor-penetration of the cyclic peptides and their conjugates have not been given in any reviews. In this review, different types of cyclic peptides, their physicochemical properties and their -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology